{
  "nodes": [
    {
      "id": "N1",
      "label": "Step 1",
      "customData": {
        "node_id": "A",
        "node_step_index": 0,
        "content": "Patient in his 50s diagnosed with NSCLC (T2aN2M1c, Stage IVB) with metastases to the bone. Primary site was the upper lobe of the right lung.",
        "clinical_data": {
          "diagnoses": [
            {
              "code": "C0678222",
              "label": "Non-small cell lung carcinoma",
              "status": "active",
              "onset_date": null
            },
            {
              "code": "C0005932",
              "label": "bone metastases",
              "status": "active",
              "onset_date": null
            }
          ],
          "imaging": [
            {
              "body_part": "C0225923",
              "modality": "other",
              "finding": "Primary site was the upper lobe of the right lung",
              "impression": "Primary site was the upper lobe of the right lung"
            }
          ]
        }
      }
    },
    {
      "id": "N2",
      "label": "Step 2",
      "customData": {
        "node_id": "B",
        "node_step_index": 1,
        "content": "Cancer size was 25 mm with invasion of the visceral pleura. No EGFR or KRAS mutations, RET, ALK, ROS1, or ALK fusion genes mutations. No other driver genetic mutations. PD-L1 (22C3) tumor proportion score was 100%.",
        "clinical_data": {
          "diagnoses": [
            {
              "code": "C34",
              "label": "Malignant neoplasm of bronchus and lung",
              "status": "active",
              "onset_date": null
            }
          ],
          "labs": [
            {
              "test": "PD-L1 (22C3) tumor proportion score",
              "value": "100",
              "unit": "%",
              "flag": "normal"
            }
          ],
          "imaging": [
            {
              "finding": "Cancer size was 25 mm with invasion of the visceral pleura",
              "date": null
            }
          ]
        }
      }
    },
    {
      "id": "N3",
      "label": "Step 3",
      "customData": {
        "node_id": "C",
        "node_step_index": 2,
        "content": "History of alcohol intake of 40 g/day up to the point of starting treatment for lung cancer. Smoked 30 cigarettes per day for 30 years.",
        "clinical_data": {
          "social_history": [
            {
              "category": "alcohol",
              "status": "past",
              "description": "History of alcohol intake of 40 g/day up to the point of starting treatment for lung cancer."
            },
            {
              "category": "smoking",
              "status": "past",
              "description": "Smoked 30 cigarettes per day for 30 years."
            }
          ]
        }
      }
    },
    {
      "id": "N4",
      "label": "Step 4",
      "customData": {
        "node_id": "D",
        "node_step_index": 3,
        "content": "Received four courses of carboplatin, pemetrexed, and pembrolizumab with a partial response.",
        "clinical_data": {
          "medications": [
            {
              "drug": "C0293934",
              "dosage": null,
              "frequency": null,
              "modality": null,
              "start_date": null,
              "end_date": null,
              "indication": null
            },
            {
              "drug": "C1637448",
              "dosage": null,
              "frequency": null,
              "modality": null,
              "start_date": null,
              "end_date": null,
              "indication": null
            },
            {
              "drug": "C4049449",
              "dosage": null,
              "frequency": null,
              "modality": null,
              "start_date": null,
              "end_date": null,
              "indication": null
            }
          ]
        }
      }
    },
    {
      "id": "N5",
      "label": "Step 5",
      "customData": {
        "node_id": "E",
        "node_step_index": 4,
        "content": "Received four courses of maintenance therapy with pemetrexed and pembrolizumab.",
        "clinical_data": {
          "medications": [
            {
              "drug": "C0972734",
              "dosage": null,
              "frequency": null,
              "modality": null,
              "start_date": null,
              "end_date": null,
              "indication": null
            },
            {
              "drug": "C1663708",
              "dosage": null,
              "frequency": null,
              "modality": null,
              "start_date": null,
              "end_date": null,
              "indication": null
            }
          ]
        }
      }
    },
    {
      "id": "N6",
      "label": "Step 6",
      "customData": {
        "node_id": "F",
        "node_step_index": 5,
        "content": "Day 194 after starting pembrolizumab, the patient developed fever of 38\u00b0C and diarrhea. CT revealed a ground-glass opacity in the right lung. Diagnosed with immune-related pneumonitis CTCAE grade 1.",
        "clinical_data": {
          "vitals": [
            {
              "type": "Fever",
              "value": "38",
              "unit": "\u00b0C",
              "timestamp": "Day 194"
            }
          ],
          "diagnoses": [
            {
              "code": "immune-related pneumonitis",
              "label": "immune-related pneumonitis",
              "status": "active",
              "onset_date": "Day 194"
            }
          ],
          "imaging": [
            {
              "type": "ground-glass opacity",
              "body_part": "right lung",
              "modality": "CT",
              "finding": "ground-glass opacity",
              "impression": "ground-glass opacity",
              "date": "Day 194"
            }
          ]
        }
      }
    },
    {
      "id": "N7",
      "label": "Step 7",
      "customData": {
        "node_id": "G",
        "node_step_index": 6,
        "content": "Received palliative radiation therapy for sacroiliac metastases, total dose of irradiation was 30 Gy/10 fr.",
        "clinical_data": {
          "procedures": [
            {
              "name": "Palliative radiation therapy",
              "approach": "other",
              "date": null,
              "location": "sacroiliac",
              "performed_by": null,
              "outcome": null
            }
          ],
          "diagnoses": [
            {
              "code": null,
              "label": "sacroiliac metastases",
              "status": "active",
              "onset_date": null
            }
          ]
        }
      }
    },
    {
      "id": "N8",
      "label": "Step 8",
      "customData": {
        "node_id": "H",
        "node_step_index": 7,
        "content": "Diagnosed with immune-related colitis CTCAE grade 2. Pemetrexed and pembrolizumab were discontinued and he was started on prednisolone at a dose of 0.5 mg/kg/day.",
        "clinical_data": {
          "diagnoses": [
            {
              "code": "C0009335",
              "label": "Colitis",
              "status": "active"
            }
          ],
          "medications": [
            {
              "drug": "C0032317",
              "dosage": "0.5 mg/kg/day",
              "frequency": "daily",
              "modality": "oral",
              "start_date": null,
              "end_date": null
            },
            {
              "drug": "C0889472",
              "dosage": null,
              "frequency": null,
              "modality": null,
              "start_date": null,
              "end_date": null
            },
            {
              "drug": "C3456946",
              "dosage": null,
              "frequency": null,
              "modality": null,
              "start_date": null,
              "end_date": null
            }
          ]
        }
      }
    }
  ],
  "edges": [
    {
      "from": "N1",
      "to": "N2",
      "data": {
        "edge_id": "A_to_B",
        "branch_flag": true,
        "content": "Transition from initial diagnosis and staging to detailed molecular characterization of the tumor."
      }
    },
    {
      "from": "N2",
      "to": "N3",
      "data": {
        "edge_id": "B_to_C",
        "branch_flag": true,
        "content": "Transition from tumor characterization to patient's relevant social history."
      }
    },
    {
      "from": "N3",
      "to": "N4",
      "data": {
        "edge_id": "C_to_D",
        "branch_flag": true,
        "content": "Transition from patient history to first-line treatment with carboplatin, pemetrexed, and pembrolizumab, resulting in a partial response.",
        "transition_event": {
          "trigger_type": "medication_change",
          "trigger_entities": [
            "C0293934",
            "C1637448",
            "C4049449"
          ],
          "change_type": "addition",
          "target_domain": "medication"
        }
      }
    },
    {
      "from": "N4",
      "to": "N5",
      "data": {
        "edge_id": "D_to_E",
        "branch_flag": true,
        "content": "Transition from initial treatment to maintenance therapy with pemetrexed and pembrolizumab.",
        "transition_event": {
          "trigger_type": "medication_change",
          "trigger_entities": [
            "C0293934",
            "C1637448",
            "C4049449"
          ],
          "change_type": "discontinuation",
          "target_domain": "medication"
        }
      }
    },
    {
      "from": "N5",
      "to": "N6",
      "data": {
        "edge_id": "E_to_F",
        "branch_flag": true,
        "content": "Transition to immune-related pneumonitis after starting pembrolizumab, CTCAE grade 1, with fever and diarrhea.",
        "transition_event": {
          "trigger_type": "symptom_onset",
          "trigger_entities": [
            "C0015967",
            "C0011991"
          ],
          "change_type": "addition",
          "target_domain": "symptom",
          "timestamp": "Day 194"
        }
      }
    },
    {
      "from": "N6",
      "to": "N7",
      "data": {
        "edge_id": "F_to_G",
        "branch_flag": true,
        "content": "Transition to palliative radiation therapy for sacroiliac metastases.",
        "transition_event": {
          "trigger_type": "procedure",
          "trigger_entities": [],
          "change_type": "addition",
          "target_domain": "procedure"
        }
      }
    },
    {
      "from": "N7",
      "to": "N8",
      "data": {
        "edge_id": "G_to_H",
        "branch_flag": true,
        "content": "Transition to immune-related colitis CTCAE grade 2, leading to discontinuation of pemetrexed and pembrolizumab and initiation of prednisolone.",
        "transition_event": {
          "trigger_type": "symptom_onset",
          "trigger_entities": [
            "C0009335"
          ],
          "change_type": "addition",
          "target_domain": "symptom"
        }
      }
    }
  ]
}